RPL17 regulates the progression of breast cancer accompanied by MAPK signaling activation

No abstract is available for this paper.

• Publication year

  2025

• Venue

  Medical Oncology

• Publication date

  2025-11-12

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/s12032-025-03117-1PMID 41222803
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Olverembatinib, a multikinase inhibitor that modulates lipid metabolism, in advanced succinate dehydrogenase-deficient gastrointestinal stromal tumors: a phase 1b study and translational research

  2025cited by this paper
• Multi-omics insights into the roles of CCNB1, PLK1, and HPSE in breast cancer progression: implications for prognosis and immunotherapy

  2025cited by this paper
• Adiponectin mediated metabolic and sphingolipid alterations in preventing endothelial dysfunction

  2025cited by this paper
• Research progress on the role of AGC kinase family in bladder cancer

  2025cited by this paper
• Breast Cancer Screening Interval: Effect on Rate of Late-Stage Disease at Diagnosis and Overall Survival

  2024cited by this paper
• Mitochondrial calcium overload contributes to cannabinoid‐induced paraptosis in hormone‐responsive breast cancer cells

  2024cited by this paper
• Collaborative Modeling to Compare Different Breast Cancer Screening Strategies: A Decision Analysis for the US Preventive Services Task Force.

  2024cited by this paper
• Repurposing proteasome inhibitors for improved treatment of triple-negative breast cancer

  2024cited by this paper
• Analysis of Breast Cancer Mortality in the US-1975 to 2019.

  2024cited by this paper
• Ribosomal proteins: the missing piece in the inflammation puzzle?

  2024cited by this paper
• Multiomic profiling of breast cancer cells uncovers stress MAPK-associated sensitivity to AKT degradation

  2024cited by this paper
• Reply to: "Breast Cancer Screening Interval: Effects of Proportions and Biases on Benefits" and "Annual Versus Biennial Mammographic Screening".

  2024cited by this paper
• Updates in Treatment of HER2-positive Metastatic Breast Cancer

  2024cited by this paper
• Immunity-and-matrix-regulatory cells enhance cartilage regeneration for meniscus injuries: a phase I dose-escalation trial

  2023cited by this paper
• Novel genetic tools improve Penicillium expansum patulin synthase production in Aspergillus niger

  2023cited by this paper
• Rucaparib inhibits lung adenocarcinoma cell proliferation and migration via the SHCBP1/CDK1 pathway

  2023cited by this paper
• E3 ligase MG53 suppresses tumor growth by degrading cyclin D1

  2023cited by this paper
• Breast Cancer Metastasis: Mechanisms and Therapeutic Implications

  2022cited by this paper
• 2′,3′,4′-Trihydroxychalcone changes estrogen receptor α regulation of genes and breast cancer cell proliferation by a reprogramming mechanism

  2022cited by this paper
• Therapeutic Potency of Induced Pluripotent Stem-Cell-Derived Corneal Endothelial-like Cells for Corneal Endothelial Dysfunction

  2022cited by this paper
• RPL17 Promotes Colorectal Cancer Proliferation and Stemness through ERK and NEK2/β-catenin Signaling Pathways

  2022influential reference
• 2′,3′,4′-Trihydroxychalcone changes estrogen receptor α regulation of genes and breast cancer cell proliferation by a reprogramming mechanism

  2021cited by this paper
• RAF-MEK-ERK pathway in cancer evolution and treatment.

  2021cited by this paper
• Long non-coding RNAs Regulated NF-κB Signaling in Cancer Metastasis: Micromanaging by Not So Small Non-coding RNAs.

  2021cited by this paper
• Targeting the MAPK Pathway in KRAS-Driven Tumors.

  2020cited by this paper
• Metastatic heterogeneity of breast cancer: Molecular mechanism and potential therapeutic targets.

  2020cited by this paper
• ERK/MAPK signalling pathway and tumorigenesis

  2020cited by this paper
• Evaluation of MDA-MB-468 Cell Culture Media Analysis in Predicting Triple-Negative Breast Cancer Patient Sera Metabolic Profiles

  2020cited by this paper
• Ductal carcinoma in situ of breast: update 2019.

  2019cited by this paper
• Cancer-associated fibroblast (CAF)-derived IL32 promotes breast cancer cell invasion and metastasis via integrin β3-p38 MAPK signalling.

  2019cited by this paper
• Cancer statistics, 2019

  2019cited by this paper
• Drug Combinations in Breast Cancer Therapy

  2019cited by this paper
• Dietary flavonoids: Nano delivery and nanoparticles for cancer therapy.

  2019cited by this paper
• Endogenous production of C-C motif chemokine ligand 2 by nasopharyngeal carcinoma cells drives radioresistance-associated metastasis.

  2019cited by this paper
• Receptor tyrosine kinases (RTKs) in breast cancer: signaling, therapeutic implications and challenges

  2018cited by this paper
• The Screening, Diagnosis, Treatment, and Follow-Up of Breast Cancer.

  2018cited by this paper
• Co-expression network analysis of gene expression profiles of HER2+ breast cancer-associated brain metastasis

  2018cited by this paper
• Lobular Carcinoma In Situ.

  2017cited by this paper
• MAPK signalling pathway in cancers: Olive products as cancer preventive and therapeutic agents.

  2017cited by this paper
• Regulation of cardiac hypertrophy and remodeling through the dual-specificity MAPK phosphatases (DUSPs).

  2016cited by this paper
• Keto acid metabolites of branched-chain amino acids inhibit oxidative stress-induced necrosis and attenuate myocardial ischemia-reperfusion injury.

  2016cited by this paper
• Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.

  2015cited by this paper
• Platelet‐rich plasma increases proliferation of tendon cells by modulating Stat3 and p27 to up‐regulate expression of cyclins and cyclin‐dependent kinases

  2015cited by this paper
• DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.

  2015cited by this paper
• Functions of ribosomal proteins in assembly of eukaryotic ribosomes in vivo.

  2015cited by this paper
• Signal integration by JNK and p38 MAPK pathways in cancer development

  2009cited by this paper
• How common are extraribosomal functions of ribosomal proteins?

  2009cited by this paper
• Control of cyclin D1 and breast tumorigenesis by the EglN2 prolyl hydroxylase.

  2009cited by this paper
• Signaling to p53: ribosomal proteins find their way.

  2009cited by this paper
• Targeting cyclin B1 inhibits proliferation and sensitizes breast cancer cells to taxol

  2008cited by this paper
• Elevation of cyclin B1, active cdc2, and HuR in cervical neoplasia with human papillomavirus type 18 infection.

  2006cited by this paper
• New roles for p21 and p27 cell-cycle inhibitors: a function for each cell compartment?

  2003cited by this paper
• Cancer statistics

  1989influential reference

• No citing papers are available for this paper.